Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legislation

Set Alert for Legislation

Latest From Legislation

Drug Pricing: US House, Senate, Taking Bicameral Go-Slow Approach

Energy & Commerce Health Subcommittee hearing on drug pricing and the supply chain begins information gathering process, leadership says. Subcommittee Chair Burgess urges stakeholders to seek consensus on market-based solutions or else.

Pricing Debate Policy & Regulation

Drug Pricing: US Senate Hearings Conclude With No Clear View On Legislation

Measures that would increase financial transparency and empower federal government to negotiate drug prices highlighted by National Academies representative who discussed recent report on drug affordability, but former Congressional Budget Office Director Holtz-Eakin warns Senate HELP Committee against taking measures that merely shift costs from one party to another.

Pricing Debate Pharmacy Benefit Management

PhRMA Sues To Block 'Unprecedented' California Price Reporting Law

Ban on WAC price increases violates Commerce Clause and reporting requirement violates First Amendment, PhRMA contends; complaint says state officials have not clarified whether law is retroactive.

BioPharmaceutical Policy

Senate Gene Editing Hearing: Trust In US FDA On Display

Discussion on cutting edge medical technology demonstrates the strong reputation FDA has built as a regulator. Witnesses in the gene editing field said FDA is doing a good job – and Congress is likely to leave it at that.

Regulation Regenerative Medicine

EU Gets Going On EMA Move To Amsterdam, Insisting The UK Pay €400m Removal Bill

Legislation drawn up by the European Commission, formally naming Amsterdam as the EMA’s new home, stresses that the UK will have to bear the costs of the agency’s relocation from London.

Brexit Legislation

Medicare Price Negotiations: HHS Nominee Suggests Adapting Part D 'Learnings' To Part B

Alex Azar talks about price negotiation in Medicare Part B, whether his biopharma industry ties would influence his decisions as head of HHS, insulin price increases and importation during the first of his confirmation hearings.

Pricing Debate Medicare
See All
UsernamePublicRestriction

Register